Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants. Chandran S, Tang Q, Sarwal M, Laszik ZG, Putnam AL, Lee K, Leung J, Nguyen V, Sigdel T, Tavares EC, Yang JYC, Hellerstein M, Fitch M, Bluestone JA, Vincenti F. Am J Transplant. 2017 Jul 4. doi: 10.1111/ajt.14415.
Transplant trials with Tregs: perils and promises. Tang Q, Vincenti F. J Clin Invest. 2017 Jun 30;127(7):2505-2512. doi: 10.1172/JCI90598.
Attenuation of donor-reactive T cells allows effective control of allograft rejection using regulatory T cell therapy. Lee K, Nguyen V, Lee KM, Kang SM, Tang Q. Am J Transplant. 2014 Jan;14(1):27-38. doi: 10.1111/ajt.12509.
Regulatory T-cell therapy for transplantation: how many cells do we need? Tang Q, Lee K. Curr Opin Organ Transplant. 2012 Aug;17(4):349-54. doi: 10.1097/MOT.0b013e328355a992
Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy. Seay HR, Putnam AL, Cserny J, Posgai AL, Rosenau EH, Wingard JR, Girard KF, Kraus M, Lares AP, Brown HL, Brown KS, Balavage KT, Peters LD, Bushdorf AN, Atkinson MA, Bluestone JA, Haller MJ, Brusko TM. Mol Ther Methods Clin Dev. 2016 Dec 24;4:178-191. doi: 10.1016/j.omtm.2016.12.003.
Inducing and Administering Tregs to Treat Human Disease. Perdigoto AL, Chatenoud L, Bluestone JA, Herold KC. Front Immunol. 2016 Jan 22;6:654. doi: 10.3389/fimmu.2015.00654.
Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q. Sci Transl Med. 2015 Nov 25;7(315):315ra189. doi: 10.1126/scitranslmed.aad4134.
Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226. Fuhrman CA, Yeh WI, Seay HR, Saikumar Lakshmi P, Chopra G, Zhang L, Perry DJ, McClymont SA, Yadav M, Lopez MC, Baker HV, Zhang Y, Li Y, Whitley M, von Schack D, Atkinson MA, Bluestone JA, Brusko TM. J Immunol. 2015 Jul 1;195(1):145-55. doi: 10.4049/jimmunol.1402381.
Targeting Treg signaling for the treatment of autoimmune diseases. Spence A, Klementowicz JE, Bluestone JA, Tang Q. Curr Opin Immunol. 2015 Dec;37:11-20. doi: 10.1016/j.coi.2015.09.002. Review.
Immunotherapy: making the case for precision medicine. Bluestone JA, Tang Q. Sci Transl Med. 2015 Mar 25;7(280):280ed3. doi: 10.1126/scitranslmed.aaa9846. No abstract available.
Regulatory T-cell therapy in transplantation: moving to the clinic. Tang Q, Bluestone JA. Cold Spring Harb Perspect Med. 2013 Nov 1;3(11). pii: a015552. doi: 10.1101/cshperspect.a015552. Review.
Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. Putnam AL, Safinia N, Medvec A, Laszkowska M, Wray M, Mintz MA, Trotta E, Szot GL, Liu W, Lares A, Lee K, Laing A, Lechler RI, Riley JL, Bluestone JA, Lombardi G, Tang Q. Am J Transplant. 2013 Nov;13(11):3010-20. doi: 10.1111/ajt.12433.
Altered balance between effector T cells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipients. Tang Q, Leung J, Melli K, Lay K, Chuu EL, Liu W, Bluestone JA, Kang SM, Peddi VR, Vincenti F. Transpl Int. 2012 Dec;25(12):1257-67. doi: 10.1111/j.1432-2277.2012.01565.x.
CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. Tang Q, Bluestone JA, Kang SM. J Mol Cell Biol. 2012 Feb;4(1):11-21. doi: 10.1093/jmcb/mjr047. Review.
Requirements for prolongation of allograft survival with regulatory T cell infusion in lymphosufficient hosts. Brennan TV, Tang Q, Liu FC, Hoang V, Bi M, Bluestone JA, Kang SM. J Surg Res. 2011 Jul;169(1):e69-75. doi: 10.1016/j.jss.2011.03.021.